Ashina, HÃ¥kan
Al-Khazali, Haidar Muhsen
Iljazi, Afrim
Ashina, Sait
Amin, Faisal Mohammad
Schytz, Henrik Winther
Funding for this research was provided by:
Rigshospitalet Research Foundation (F-23340-02)
Article History
Received: 13 May 2022
Accepted: 7 July 2022
First Online: 8 August 2022
Declarations
:
: Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was approved by the relevant ethics committee.
: Not applicable.
: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: S.A. has been a consultant, speaker, or scientific adviser for Allergan, Amgen, Eli Lilly, Novartis, Promius, Satsuma, Supernus, and Theranica, outside of the submitted work. F.M.A. has been a consultant, speaker, or scientific adviser for Eli Lilly, Lundbeck, Novartis, and Teva, outside of the submitted work. H.W.S. has been a consultant, speaker, or scientific adviser for Novartis, Eli Lilly, Lundbeck, Abbvie, and Teva, outside of the submitted work. All other authors declare no competing interests.